Skip navigation

Uncover the Risks Associated with Anti-Bribery and Anti-Corruption, Data Privacy and HCP Engagement

March 13-14, 2018
  • Shanghai, China

Backed by 20 years of global compliance programming and education, CBI’s Pharmaceutical Compliance Congress (PCC) Asia is the premier event for compliance teams to gain novel approaches and advanced strategies for the quickly transforming regulatory landscape.

With rapidly evolving global regulations deeply affecting business operations in Asia, multi-national life sciences companies must be more attentive than ever. Increasing anti-bribery and anti-corruption requirements from the U.S., UK and local Asian regulatory bodies are driving compliance professionals to build and maintain effective compliance programs that not only meet these multi-jurisdictional requirements, but align with their overall business objectives.

This fully-packed two day forum features in-depth content and insights around the most important compliance and legal issues in China, South Korea, Japan, Indonesia, India, Thailand, Vietnam, Malaysia, the Philippines and Australia. Join the brightest minds and most influential stakeholders in life sciences compliance to benchmark, exchange strategies and learn about the latest guidance and laws, surrounding bribery and corruption, HCP engagement, transparency, data privacy, competition, intellectual property and more.

Pivotal Discussions, Unparalleled Insights and Expert Commentary Including:

  • Ethics and compliance as a strategic business partner
  • Compliance training for bridging cultural differences
  • Anti-bribery and anti-corruption efforts in China, South Korea and
    other countries in the region
  • New transparency reporting requirements in Japan, Indonesia,
    The Philippines and South Korea
  • China’s two-invoice policy system
  • Determining fair market value (FMV) for healthcare
    provider service engagements
  • Data protection and cybersecurity trends in the region
  • Risk planning and mitigation during R&D and the clinical trial lifecycle

Download the Conference Preview

Previous Attendee Acclaim:

CBI always provides insightful speakers who share their worldly experience on important healthcare topics.

Senior Director, Compliance, GlaxoSmithKline

This is a terrific opportunity to benchmark practices.

VP and CCO, Haemonetics Corporation

Pharmaceutical Compliance Congress Asia

Uncover the Risks Associated with Anti-Bribery and Anti-Corruption, Data Privacy and HCP Engagement

Backed by 20 years of global compliance programming and education, CBI’s Pharmaceutical Compliance Congress (PCC) Asia is the premier event for compliance teams to gain novel approaches and advanced strategies for the quickly transforming regulatory landscape.

With rapidly evolving global regulations deeply affecting business operations in Asia, multi-national life sciences companies must be more attentive than ever. Increasing anti-bribery and anti-corruption requirements from the U.S., UK and local Asian regulatory bodies are driving compliance professionals to build and maintain effective compliance programs that not only meet these multi-jurisdictional requirements, but align with their overall business objectives.

This fully-packed two day forum features in-depth content and insights around the most important compliance and legal issues in China, South Korea, Japan, Indonesia, India, Thailand, Vietnam, Malaysia, the Philippines and Australia. Join the brightest minds and most influential stakeholders in life sciences compliance to benchmark, exchange strategies and learn about the latest guidance and laws, surrounding bribery and corruption, HCP engagement, transparency, data privacy, competition, intellectual property and more.

Pivotal Discussions, Unparalleled Insights and Expert Commentary Including:

  • Ethics and compliance as a strategic business partner
  • Compliance training for bridging cultural differences
  • Anti-bribery and anti-corruption efforts in China, South Korea and
    other countries in the region
  • New transparency reporting requirements in Japan, Indonesia,
    The Philippines and South Korea
  • China’s two-invoice policy system
  • Determining fair market value (FMV) for healthcare
    provider service engagements
  • Data protection and cybersecurity trends in the region
  • Risk planning and mitigation during R&D and the clinical trial lifecycle

Download the Conference Preview

Previous Attendee Acclaim:

CBI always provides insightful speakers who share their worldly experience on important healthcare topics.

Senior Director, Compliance, GlaxoSmithKline

This is a terrific opportunity to benchmark practices.

VP and CCO, Haemonetics Corporation